Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $42.13 Average PT from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $42.13.

A number of equities research analysts have recently commented on ARWR shares. StockNews.com raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, May 14th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Finally, Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th.

Arrowhead Pharmaceuticals Stock Performance

ARWR traded down $0.98 on Friday, reaching $15.31. The company had a trading volume of 1,893,634 shares, compared to its average volume of 1,496,857. The stock has a 50-day moving average price of $13.33 and a 200-day moving average price of $17.73. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $30.41. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market capitalization of $2.11 billion, a PE ratio of -2.96 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same period in the previous year, the company posted ($1.02) earnings per share. As a group, research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the transaction, the chief executive officer now directly owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. This represents a 3.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 275,880 shares of company stock worth $4,034,037 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock worth $60,962,000 after buying an additional 2,774,933 shares during the period. Avoro Capital Advisors LLC grew its position in Arrowhead Pharmaceuticals by 25.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock worth $208,889,000 after buying an additional 2,222,223 shares during the period. Norges Bank acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $38,622,000. Vanguard Group Inc. grew its position in Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after buying an additional 1,018,273 shares during the period. Finally, Farallon Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $11,821,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.